BioCentury
ARTICLE | Clinical News

Diazoxide choline controlled release: Phase IIb data

May 25, 2009 7:00 AM UTC

In a double-blind Phase IIb trial in 90 patients, DCCR met the primary endpoint of significantly reducing triglycerides, with a 30% placebo-controlled median reduction at week 8. The company said no "...